Protagonist Therapeutics, Inc.
PTGX
$56.25
$0.040.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.45% | -34.02% | 624.06% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.45% | -34.02% | 624.06% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -34.45% | -34.02% | 624.06% | -- | -- |
| SG&A Expenses | 3.34% | 1.24% | 29.77% | 32.71% | 27.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.98% | 8.60% | 18.18% | 14.01% | 13.37% |
| Operating Income | -84.25% | -81.69% | 369.98% | 197.32% | 203.43% |
| Income Before Tax | -68.84% | -65.49% | 453.88% | 223.20% | 225.43% |
| Income Tax Expenses | -34.26% | -73.12% | -- | -- | -- |
| Earnings from Continuing Operations | -69.38% | -65.34% | 448.54% | 221.61% | 223.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.38% | -65.34% | 448.54% | 221.61% | 223.50% |
| EBIT | -84.25% | -81.69% | 369.98% | 197.32% | 203.43% |
| EBITDA | -83.77% | -81.25% | 373.72% | 198.58% | 204.81% |
| EPS Basic | -69.75% | -65.83% | 405.40% | 207.96% | 204.11% |
| Normalized Basic EPS | -69.23% | -66.01% | 410.04% | 209.36% | 205.73% |
| EPS Diluted | -73.08% | -69.04% | 382.22% | 201.24% | 197.50% |
| Normalized Diluted EPS | -72.33% | -69.10% | 388.89% | 203.27% | 199.77% |
| Average Basic Shares Outstanding | 3.66% | 4.71% | 8.52% | 13.22% | 17.51% |
| Average Diluted Shares Outstanding | 3.57% | 4.60% | 10.84% | 15.14% | 19.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |